RxDoctor Payments DataLook up a doctor →

John Park, MD

Vascular Surgery · Omaha, NENPI 1023394665

Payments from drug & device makers

$615,994in general payments, 2019–2025

Across 1,682 payments — averaging $366.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$208K
  • Bard Peripheral Vascular, Inc.$124K
  • Endologix LLC$99K
  • Silk Road Medical, Inc.$50K
  • Penumbra, Inc.$46K
  • Johnson & Johnson$21K
  • plus $70K from 44 others

What the payments were for

  • Consulting fees$215,72742%
  • Speaking & faculty fees$155,13031%
  • Travel & lodging$75,97915%
  • Food & beverage$61,09212%
  • Entertainment$520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$615,994 in reported general payments places this provider in the 95th percentile of 35 vascular surgery providers in Nebraska.

See all vascular surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$307,876
Medicare patients
1,185
Services billed
2,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban42$41,230
ClopidogrelClopidogrel Bisulfate105$604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$20,586$41,23042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 vascular surgery providers in Nebraska.

Other vascular surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →